Financial Data and Key Metrics Changes - In Q4 2025, net sales increased approximately 29% to $184.5 million, with gross profit growing approximately 35% to $48.1 million and gross margin increasing 120 basis points to 26.1% [19][20] - Full year 2025 net sales grew approximately 15% to a record $656.1 million, with net income and diluted earnings per share reaching $46.9 million and $1.96, respectively [21][30] - Adjusted EBITDA for 2025 increased approximately 23% to $97.9 million, with margins increasing 90 basis points to 14.9% [21][30] Business Line Data and Key Metrics Changes - Work Truck Attachments segment saw Q4 net sales and Adjusted EBITDA both increase by more than 50% to $83.1 million and $13.9 million, respectively, driven by increased snowfall [22][23] - For the full year 2025, Work Truck Attachments net sales increased approximately 16% to $295.7 million, with Adjusted EBITDA also improving by 16% to $56.2 million [23] - Work Truck Solutions segment achieved record results in Q4 with net sales increasing approximately 13% to $101.5 million and Adjusted EBITDA growing approximately 22% to $11.9 million [24] Market Data and Key Metrics Changes - The company reported above-average snowfall in key markets, which positively impacted demand and sales [9][10] - Retail sales for plow and hopper inventories were confirmed to be below the 10-year averages, indicating strong market demand [10] - The municipal customer demand remains robust, contributing to a near-record backlog in the Work Truck Solutions segment [11] Company Strategy and Development Direction - The company has established a strategic framework focusing on three pillars: optimize, expand, and activate, aimed at driving sustainable long-term value creation [6][13] - Plans for geographic growth and new product offerings are underway, including the opening of a new facility in Missouri to enhance service capabilities [15][16] - The company is pursuing strategic M&A opportunities, having recently acquired Venco Venturo to diversify its portfolio [16][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to capitalize on favorable weather conditions and operational strengths to drive growth in 2026 [5][31] - The outlook for 2026 includes expected net sales between $710 million and $760 million, with Adjusted EBITDA projected to range from $100 million to $120 million [30][31] - Management noted that the effective tax rate is expected to be approximately 24%-25%, assuming stable economic conditions [31] Other Important Information - Total liquidity at the end of the quarter was $127.8 million, with free cash flow increasing 91% to $63.6 million [25][26] - The company plans to maintain its quarterly cash dividend of $0.295 per share and has $38 million remaining on its share repurchase authority [27][28] Q&A Session Summary Question: Which segment might have the better growth outlook for 2026? - Management expects mid to high single-digit growth in Solutions, with the remaining growth anticipated in Attachments due to the Venco acquisition and higher snowfall [36] Question: How is the integration of Venco Venturo going? - Integration is progressing well, with no surprises, and it is expected to be accretive to earnings per share and free cash flow [43][44] Question: What is the outlook for parts and accessories performance? - Parts and accessories accounted for approximately 14%-15% of sales, with high margins contributing positively to overall performance [54] Question: What are the expected normalized margins for Attachments? - Normalized margins for Attachments are expected to reach the mid-twenties with average volumes [91]

Group 1 - The core viewpoint of the article highlights that Haijia Medical (06078) has seen a stock price increase of over 4%, currently trading at 12.6 HKD with a transaction volume of 40.78 million HKD [1] - Haijia Medical announced a share buyback of approximately 6.0098 million HKD for 493,800 shares on December 17 [1] - The company plans to utilize its buyback authorization to repurchase shares in the open market for a total price of no less than 300 million RMB [1] Group 2 - According to CMB International, the pressure on cost control is easing, and the elimination of outdated production capacity is expected to allow private medical institutions to return to a faster growth trajectory [1] - CMB International recommends high-quality stocks like Haijia Medical, which are expected to see a rebound in short-term performance and have a clear long-term expansion path [1]